In brief
In a bid to address rising healthcare costs and improve access to obesity treatments, President Trump revealed a deal with drugmakers Eli Lilly and Novo Nordisk to lower the prices of their medications, Zepbound and Wegovy. Starting next year, Medicare will provide coverage for these GLP-1 receptor agonist drugs, previously limited due to high costs and inconsistent insurance support. The administration aims to alleviate financial burdens on patients, with forthcoming lower prices for uninsured individuals starting in January. However, doctors and experts remain cautious about the potential impact on access and affordability.
WASHINGTON (AP) — In a strategic initiative, President Donald Trump announced a new partnership with pharmaceutical giants Eli Lilly and Novo Nordisk aimed at expanding coverage and reducing costs for their popular obesity medications, Zepbound and Wegovy.
These drugs are part of an innovative class known as GLP-1 receptor agonists, which have gained popularity for their effectiveness in assisting weight loss. However, high prices—averaging around $500 monthly—have limited access for many patients, and insurance coverage has been inconsistent.
Under the new policy, Medicare patients will gain access to these treatments starting next year, along with phased-in lower prices for uninsured individuals, with initial doses of new pill versions expected to cost $149 per month if approved.
This announcement reflects the Trump administration's broader efforts to tackle soaring drug prices amid growing cost-of-living concerns among voters, especially in the wake of Republican losses in recent elections where economic issues dominated voter priorities.
The Growing Demand for Obesity Treatments
The rising demand for obesity treatments signals a critical shift in the healthcare landscape. Clinical trials of these drugs have shown that patients can lose between 15% to 22% of their body weight. However, many Americans find these options unaffordable without adequate insurance support. Medicare has historically not covered weight loss drugs, with previous attempts to change this policy falling short.
Increased access through Medicare could significantly benefit the estimated 30 million Americans who struggle with obesity, a move that clinicians and experts are cautiously optimistic about. Doctors are hoping that these changes will alleviate financial stress for many patients who have been juggling multiple jobs or deferring retirement just to afford their medication.
A Step Toward Affordability
The announcement has generally been well-received by healthcare professionals who emphasize the need for broader accessibility to these impactful treatments. Some doctors, however, remain skeptical of the effectiveness of the plan until more definitive details are made available.
As part of the initiative, lower prices will also be introduced for Medicaid programs alongside the new direct purchase initiative from drug manufacturers starting in January. However, skeptics stress the importance of following through on this commitment to ensure lasting change in the affordability and accessibility of obesity medications.
